Balimbingan, Virginia B.
HRN: 24-57-51 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/22/2024
CO-AMOXICLAV 625MG (TAB)
10/22/2024
10/26/2024
ORAL
625 Mg
Every 8 Hours
S/P AKA
Waiting Final Action
Indication: Empiric Type of Infection: Bone & JointSkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes